International Society for Pharmacoeconomic and Outcome Research (ISPOR)
Regarded as a leading hospital in Queens, New York, we offer a wide variety of patient-centered, expert care to our community.
MS Disease Management Approach Reduces Payer Cost
- Innovative approach to collaborating HUB and Specialty Pharmacy to drive better patient outcomes.
- Leveraging Disease Management & Technology to help MS patients adhere to the Treatment plan.
Charles A. Stevens, JD, MBA, COPILOT Provider Services | Bincy Varghese, PharmD, CareMed Specialty Pharmacy | Moby Kazmi, MD, COPILOT Provider Services | Gabe Tochterman, BS, COPILOT Provider Services
Objectives
Determine if patients who enroll in a CareMed Specialty Pharmacy and COPILOT Provider Services led disease management program for the treatment of Multiple Sclerosis (MS) with Subcutaneous (SC) / Inter-muscular (IM) therapy are more adherent than patients who are not enrolled in such a support program. Recent MS study results show that adherence of patients on Subcutaneous (SC) / Inter-muscular (IM) therapy is 70.8%; these patients were not supported by any disease management programs. Further, MS patients who took their medication consistently were found to have 66% fewer emergency room (ER) visits and 23% lower medical costs than those MS patients who did not. Average MS-related medical costs for patients in the lowest medication adherence range were $23,253, while those in the highest adherence range averaged $17,814, resulting in an average savings over $5,400.
Methods
- Number of missed doses in 4 weeks
- Reason dose was missed
- Perceived side effects
- Ease of administration
- Medication satisfaction
Results
97.4% of all Subcutaneous (SC) / Inter-muscular (IM) therapy doses for participating patients in CareMed’s and COPILOT disease management program were administered based on physician treatment plans compared to 70.8% of all SC/IM therapy doses for patients not participating in a disease management program.
Non-Compliance Analysis N=43 Patients
Conclusions
Pharmacy led MS focused disease management programs can support better adherence resulting in fewer ER visits and a reduction in overall medical costs. Further study regarding disease management programs and their impact on outcomes and costs is recommended.
Work Cited
- Consortium of Multiple Sclerosis Centers 201 S Annual Meeting.
- MS Treatment Aanerence Questionnaire.
- Oral Ms Drugs May Not Automatically Boost Mnerence June 2015. nnp,//www.me<1pagetooay.com/ MeetingCoverage/CMSC/51882.
- ES Data 2015 5. Truven Healtn Analytics Marketscan Meeting.
